Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase II trial tests the safety, side effects, and effectiveness of asparaginase Erwinia chrysanthemi during induction chemotherapy followed by consolidation chemotherapy in treating high-risk adults with newly diagnosed acute lymphoblastic leukemia or lymphoblastic lymphoma. Asparaginase Erwinia chrysanthemi, a type of protein synthesis inhibitor, is a drug that is made up of the enzyme asparaginase, which comes from the bacterium Erwinia chrysanthemi, and is used with other drugs in people who cannot take asparaginase that comes from the bacterium E. coli. Asparaginase Erwinia chrysanthemi breaks down the amino acid asparagine and may stop the growth of cancer cells that need asparagine to grow. It may also kill cancer cells. Induction therapy, consisting of cytarabine, dexamethasone, vincristine, daunorubicin, methotrexate, and rituximab, is the first choice of treatment. Consolidation therapy, consisting of cyclophosphamide, cytarabine, vincristine, mercaptopurine, methotrexate and rituximab, is given after initial therapy to kill any remaining cancer cells. Vincristine is in a class of medications called vinca alkaloids. It works by stopping cancer cells from growing and dividing and may kill them. Methotrexate is in a class of medications called antimetabolites. It is also a type of antifolate. Methotrexate stops cells from using folic acid to make deoxyribonucleic acid (DNA) and may kill cancer cells. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's DNA and may kill cancer cells. It may also lower the body's immune response. Cytarabine and mercaptopurine stop cells from making DNA and may kill cancer cells. They are a type of antimetabolite. Daunorubicin blocks a certain enzyme needed for cell division and DNA repair and may kill cancer cells. It is a type of anthracycline antibiotic and a type of topoisomerase inhibitor. Dexamethasone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. Giving asparaginase Erwinia chrysanthemi with induction chemotherapy followed by consolidation chemotherapy may be safe, tolerable, and/or effective in treating high-risk adults with newly diagnosed acute lymphoblastic leukemia or lymphoblastic lymphoma.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek od 18 do 39 lat z wskaźnikiem masy ciała powyżej 30, lub wiek 40-54 lata bez względu na wagę
- •Nowo zdiagnozowana białaczka lymphoblastyczna (typ bez chromosomu Philadelphia) lub chłoniak lymphoblastyczny
- •Ogólny stan zdrowia pozwalający na leczenie (wskaźnik ECOG nie wyższy niż 2)
- •Sprawna praca wątroby - stężenie bilirubiny nie wyższe niż 1,5 razy норма
- •Sprawna praca nerek - oczyszczanie kreatyniny co najmniej 60 mL/min na dobę
- •Prawidłowe parametry krwawienia - wyniki badań PT i aPTT w normie
- •Sprawna praca serca - wyrzutność lewej komory co najmniej 50%
- •Brak aktywnego zapalenia wątroby typu B
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 54 Years
- Last updated (source)
- October 13, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (8)
City of Hope at Phoenix
Phoenix, United States
City of Hope Medical Center
Duarte, United States
City of Hope at Irvine Lennar
Irvine, United States
UC San Diego Moores Cancer Center
La Jolla, United States
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, United States
University of Chicago Comprehensive Cancer Center
Chicago, United States
Memorial Sloan Kettering Cancer Center
New York, United States
Cleveland Clinic Foundation
Cleveland, United States
Trial contact
Tibor Kovacsovics, MD
Ibrahim Aldoss
Ibrahim Aldoss
PRINCIPAL_INVESTIGATOR
James K. Mangan
James K. Mangan
PRINCIPAL_INVESTIGATOR
Patricia A. Young
Patricia A. Young
PRINCIPAL_INVESTIGATOR
Wendy Stock
Wendy Stock
PRINCIPAL_INVESTIGATOR
Mark B. Geyer
Mark B. Geyer
PRINCIPAL_INVESTIGATOR
Anjali S. Advani
Anjali S. Advani
PRINCIPAL_INVESTIGATOR
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 10/14/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.